August 23, 2012 — The U.S. Food and Drug Administration (FDA) has cleared Toshiba’s Aquilion RXL Edition computed tomography (CT) system. The system reconstructs images faster and includes the latest dose reduction technologies, providing faster, safer information to physicians and patients.
Aquilion RXL brings advanced radiation dose reduction technology to the 16-detector row CT system with Toshiba’s Adaptive Iterative Dose Reduction 3D (AIDR 3D). AIDR 3D lowers radiation dose compared with conventional scanning, aiding clinicians in accurate diagnoses and treatment planning. It is a sophisticated algorithm designed to work in both the raw data and image data spaces, reducing noise while attempting to maintain image quality. The system also features Toshiba’s NEMA XR 25 Dose Check Software, which improves user awareness of the radiation dose administered to patients.
Additionally, Aquilion RXL incorporates Toshiba’s sophisticated suite of SURE technologies, increasing clinical capabilities and significantly improving productivity.
“Aquilion RXL is the ideal system for healthcare facilities looking for a safe, efficient and accurate CT system, combining performance and value for every-day imaging needs,” said Satrajit Misra, senior director, CT business unit, Toshiba. “The integrated AIDR 3D radiation dose reduction technology creates safer exams for improved patient care.”
For more information: www.medical.toshiba.com
April 29, 2026 
